NCT04522544 - Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 15, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Hepatocellular Carcinoma Non-resectableHCC

Interventions

DRUG

Tremelimumab

300 mg Tremelimumab C1D1

DRUG

Durvalumab

1500 mg Durvalumab C1D1 + Q4W (max. 13 cycles)

PROCEDURE

Y-90 SIRT

Locoregional therapy will be performed as a standard-of-care procedure

PROCEDURE

DEB-TACE

Locoregional therapy will be performed as a standard-of-care procedure

Trial Locations (12)

23538

RECRUITING

Universtitätsklinikum Schleswig-Holstein, Lübeck

30625

RECRUITING

Medizinische Hochschule Hannover, Hanover

37075

RECRUITING

Universitätsmedizin Göttingen, Göttingen

45147

RECRUITING

Universitätsklinikum Essen, Essen

48149

RECRUITING

Universitätsklinikum Münster, Münster

50937

RECRUITING

Universitätsklinikum Köln, Cologne

53127

RECRUITING

Universitätsklinikum Bonn, Bonn

72076

RECRUITING

Universitätsklinikum Tübingen, Tübingen

79106

WITHDRAWN

Universitätsklinikum Freiburg, Freiburg im Breisgau

81675

RECRUITING

Klinikum rechts der Isar der Technischen Universität München, München

81925

RECRUITING

München Klinik Bogenhausen, München

07747

RECRUITING

Universitätsklinikum Jena, Jena